Canada Royal Enoch Phytomedicine Ltd. has achieved a significant milestone with its ginsenoside supplement, Redsenol-1 Plus Noble Ginsenosides, becoming the first product in the global multi-component ginsenoside industry to be included in the National Cancer Institute's Drug Dictionary. The NCI Drug Dictionary, a premier reference for technical definitions of cancer-related drugs and agents, now defines Redsenol-1 Plus as an oral and herbal supplement containing sixteen ginsenosides derived from ginseng. This definition encompasses rare ginsenoside monomers including Rg3, Rh1, Rh2, and others, distinguishing it from conventional ginseng extract supplements.
Unlike typical ginseng supplements that contain approximately 4% total ginsenosides, Redsenol-1 Plus features a 20% concentration of highly bioactive and absorbable rare ginsenosides. The company has developed proprietary extraction and processing technologies that enable large-scale production of these valuable compounds. Dr. Peihua Yu, founder and CEO of Canada Royal Enoch Phytomedicine, emphasized the significance of this inclusion, noting that it provides researchers with a standardized definition of the supplement's components.
The recognition coincides with an ongoing clinical trial investigating the supplement's potential in managing cancer-related fatigue. The clinical trial, conducted by KGK Science, Inc., is a rigorous triple-blind, placebo-controlled study designed to evaluate Redsenol-1 Plus's efficacy in mitigating cancer-related fatigue. Successful outcomes could position the supplement as an innovative supportive care option for cancer patients experiencing treatment-related symptoms.
This achievement underscores Canada Royal Enoch Phytomedicine's commitment to advancing scientific understanding of ginsenoside applications in oncology and health research. By developing a supplement with a unique ginsenoside profile, the company has distinguished itself in the global market of natural health products. The inclusion in the NCI Drug Dictionary represents a critical step toward mainstream acceptance of standardized herbal supplements in cancer care and research protocols.
